• Please log in or register to access this feature.

Rheumatoid Arthritis

You have full text access to this OnlineOpen article

Predictors for remission in rheumatoid arthritis patients: A systematic review

  1. Wanruchada Katchamart1,7,*,
  2. Sindhu Johnson2,
  3. Hsing-Ju Lucy Lin3,
  4. Veerapong Phumethum4,8,
  5. Carine Salliot5,
  6. Claire Bombardier6,†,‡

Article first published online: 16 MAR 2010

DOI: 10.1002/acr.20188

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 8, pages 1128–1143, August 2010

Additional Information

How to Cite

Katchamart, W., Johnson, S., Lin, H.-J. L., Phumethum, V., Salliot, C. and Bombardier, C. (2010), Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res, 62: 1128–1143. doi: 10.1002/acr.20188

Author Information

  1. 1

    University of Toronto, Toronto, Ontario, Canada

  2. 2

    University Health Network, University of Toronto, Toronto, Ontario, Canada

  3. 3

    University of Toronto, Toronto, Ontario, Canada

  4. 4

    University of Toronto, Toronto, Ontario, Canada

  5. 5

    Paris Descartes University and UPRES-EA 4058, Assistance Publique Hôpitaux de Paris, Cochin Hospital, Paris, France

  6. 6

    University of Toronto and Toronto General Research Institute, University Health Network, Toronto, Ontario, Canada

  7. 7

    Siriraj Hospital, Mahidol University, Bangkok, Thailand

  8. 8

    Prapokklao Hospital, Chantaburi, Thailand

  1. †

    Dr. Bombardier holds a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care.

  2. ‡

    Dr. Bombardier has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Schering, Roche, Biogen Idec, and PESI Healthcare, and (more than $10,000 each) from Wyeth, Abbott, and Abbott Canada.

*Division of Rheumatology, Department of Medicine, Siriraj Hospital, 2 Prannok Road, Bangkok-noi, Bangkok 10700, Thailand

  1. †

    Dr. Bombardier holds a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care.

  2. ‡

    Dr. Bombardier has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Schering, Roche, Biogen Idec, and PESI Healthcare, and (more than $10,000 each) from Wyeth, Abbott, and Abbott Canada.

Publication History

  1. Issue published online: 3 AUG 2010
  2. Article first published online: 16 MAR 2010
  3. Manuscript Accepted: 1 MAR 2010
  4. Manuscript Received: 30 SEP 2009

Funded by

  • Canadian Institutes of Health Research Clinician Scientist Award

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (139K)

REFERENCES

  • 1
    Bykerk V, Keystone E. What are the goals and principles of management in the early treatment of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2005; 19: 147–61.
  • 2
    Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005; 64: 1294–8.
  • 3
    Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443–9.
  • 4
    Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 264: 263–9.
  • 5
    Alonso-Ruiz A, Pijoan J, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor α drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 52.
  • 6
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 7
    Hayden JA, Cote P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427–37.
  • 8
    Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999; 38: 228–34.
  • 9
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al, for the FIN-RACo Trial Group. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894–8.
    Direct Link:
  • 10
    Molenaar ET, Voskuyl AE, van der Horst-Bruinsma IE, Schreuder GM, Zanelli E, Dijkmans BA. Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 2002; 61: 351–3.
  • 11
    Gossec L, Dougados M, Goupille P, Cantagrel A, Sibilia J, Meyer O, et al. Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis 2004; 63: 675–80.
  • 12
    Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005; 64: 38–43.
  • 13
    Kuuliala A, Leirisalo-Repo M, Mottonen T, Hannonen P, Nissila M, Kautiainen H, et al. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug. Clin Exp Rheumatol 2005; 23: 243–6.
  • 14
    Vazquez I, Graell E, Gratacos J, Canete JD, Vinas O, Ercilla MG, et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol 2007; 25: 231–8.
  • 15
    Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdzik M. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 2007; 8: 1551–9.
  • 16
    Forslind K, Hafstrom I, Ahlmen M, Svensson B, and the BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007; 66: 46–52.
  • 17
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008; 35: 562–71.
  • 18
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, on behalf of the British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 1786–94.
    Direct Link:
  • 19
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, for the British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558–65.
  • 20
    Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al, for the TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 3928–39.
    Direct Link:
  • 21
    Gonzalez-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1675–8.
  • 22
    Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 495–9.
  • 23
    Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 2008; 59: 32–41.
    Direct Link:
  • 24
    Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: the GISEA study. J Rheumatol 2007; 34: 1670–3.
  • 25
    Liang GC, Cordero M, Dyer A, Chang RW. Current tumor necrosis factor-α inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1662–5.
  • 26
    Lee DM, Phillips R, Hagan EM, Chibnik LB, Costenbader KH, Schur PH. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 201–8.
  • 27
    Linn-Rasker SP, van der Helm-van Mil AH, van Gaalen FA, Kloppenburg M, de Vries RR, le Cessie S, et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65: 366–71.
  • 28
    Katz P, Criswell L. Differences in symptom reports between men and women with rheumatoid arthritis. Arthritis Care Res 1996; 9: 441–8.
    Direct Link:
  • 29
    Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al, and the QUEST-RA Group. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009; 11: R7.
  • 30
    Deighton CM, Surtees D, Walker DJ. Influence of the severity of rheumatoid arthritis on sex differences in Health Assessment Questionnaire scores. Ann Rheum Dis 1992; 51: 473–5.
  • 31
    Sokka T, Makinen H, Hannonen P, Pincus T. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1020–3.
  • 32
    Aletaha D, Smolen J. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol 2006; 24 Suppl 43 : S45–51.
  • 33
    Outcome measures in rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 526–91.
  • 34
    Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum 2008; 59: 1371–7.
    Direct Link:
  • 35
    Hayden JA, Cote P, Steenstra IA, Bombardier C. Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies. J Clin Epidemiol 2008; 61: 552–60.
View Full Article with Supporting Information (HTML) Get PDF (139K)